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investigate the cost-effectiveness of including HPV vaccination in the preventive strat-
egy of cervical cancer. METHODS: We developed an interactive Markov model based 
on modeling disease progression. Data on prevalences, incidences, test characteristics, 
efﬁ cacy of vaccination and of cancer treatments, and quality of life of cervical cancer 
patients were taken from the scientiﬁ c literature. Data on the costs of screening and 
of cancer treatments were provided by the Hungarian National Health Fund. We 
applied 5% discount rate for both cost and utility values. The effect of herd immunity 
was taken into account in the model. GDP PPP exchange rate in 2009 was employed 
to convert local currency to EUR (1 EUR = 158 HUF). RESULTS: We analyzed the 
cost-effectiveness of different scenarios. In case of the most likely scenario to come 
through—vaccination at age 12, coverage 80%, vaccine effectiveness against 
HPV16/18 (responsible for 72% of cervical cancers caused by HPV) being 95%, 
vaccine is efﬁ cient for at least 20 years, the effectiveness of the screening program is 
not improved radically—the ICER for vaccination was c49,587/QALY compared to 
no screening. CONCLUSIONS: As disease burden of cervical cancer is high in 
Hungary, including HPV vaccination in the preventive strategy of cervical cancer 
would result in a cost-effectiveness ratio below the implicit upper threshold (3× GDP/
capita = c49,986 in PPP).
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OBJECTIVES: Bevacizumab in combination with platinum-based chemotherapy 
improves progression-free survival (PFS) over chemotherapy alone in advanced or 
metastatic NSCLC. The aim of this analysis was to assess potential cost savings for 
society derived from the clinical beneﬁ ts of bevacizumab-based therapy in metastatic 
NSCLC patients returning to work in France. METHODS: Indirect cost calculation 
was performed using human capital approach in the population of progression free 
metastatic NSCLC patients. Clinical outcomes in terms of PFS from the two bevaci-
zumab phase III trials (Reck et al. 2009, Sandler et al. 2006) were applied to the 
incidence cases of nonsquamous metastatic NSCLC patients in France, taking into 
account only age groups eligible to work. Clinical experts were consulted to estimate 
the percentage of PFS patients who return to work after the induction phase. It was 
estimated that 20% of PFS patients, below 55 years of age and with performance 
status 0–1 would maintain their prior employment status (60% part time, 40% full 
time). Cost savings were analyzed for 1 year and 1.5 year time horizons applying 
French labor costs. RESULTS: Indirect cost savings per patient returning to work were 
c21,667 at year 1 and c39,001 at year 1.5. a change in employment pattern (40% 
part time, 60% full time) led to an approximate 14% increase of savings for both 
time horizons (c24,763 at year 1 and c44,573 at year 1.5). a 10% alteration of labor 
cost in either direction resulted in cost savings that were 10% higher/lower. CON-
CLUSIONS: Bevacizumab-based therapy could result in considerable cost savings in 
progression-free NSCLC patients. This societal economic beneﬁ t adds to the patients’ 
clinical beneﬁ t of increased survival outcomes.
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OBJECTIVES: First-line treatment of advanced or metastatic NSCLC patients with 
bevacizumab demonstrated signiﬁ cantly improved progression-free survival (PFS) when 
added to platinum-based chemotherapy (Reck 2009; Sandler 2006). The aim of this 
analysis was to investigate whether this clinical beneﬁ t would translate into cost savings 
due to reduced productivity losses in metastatic NSCLC patients who return to work 
while treated with bevacizumab-based therapy in Germany. METHODS: Potential cost 
savings were calculated on the basis of reduced productivity losses for patients returning 
back to work during PFS periods of 1 and/or 1.5 years, applying the human capital 
approach. The percentage of progression-free patients with ECOG performance status 
0 and 1 was derived from the two bevacizumab phase III trials. Epidemiologic data as 
well as country-speciﬁ c employment rates were applied stepwise to estimate the meta-
static NSCLC patient population eligible to work and employed at diagnosis. It was 
assumed that 20% of progression-free patients would return to work after the induction 
phase while maintaining their prior employment status (40% full time). Cost savings 
related to productivity losses were calculated by applying German labor cost data to the 
derived population of interest. Results were weighted according to prescribing patterns 
of bevacizumab combination regimens (bevacizumab/cisplatin/gemcitabine or bevaci-
zumab/carboplatin/paclitaxel). Sensitivity analyses were performed for employment pat-
terns and labor cost. RESULTS: Mean cost savings were c21,171 at year 1 and c38,107 
at year 1.5 per progression-free patient returning to work in Germany. a change in 
employment pattern (60% full time) led to an approximate 14% increase of savings for 
both time horizons (c24,195 at year 1 and c43,551 at year 1.5). a 10% alteration of 
labor cost in either direction resulted in cost savings that were 10% higher/lower. 
CONCLUSIONS: In addition to its PFS beneﬁ ts bevacizumab-based therapy could result 
in considerable cost savings in progression free metastatic NSCLC patients.
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OBJECTIVES: Novel treatment options for NSCLC patients were shown to improve 
survival outcomes. Thus, it is of interest whether published evidence can be found on 
work productivity and employment consequences for this patient group and their 
informal caregivers, and on respective indirect cost data. METHODS: A systematic 
literature search from 1990 onward was performed using 19 bibliographic databases 
available via DIMDI (German Institute of Medical Documentation and Information), 
supplemented by searches for other publicly available sources such as abstracts at 
major health economic and clinical conferences, HTAs, and further gray literature. 
RESULTS: So far, published indirect cost data are elusive and rather limited to overall 
lung cancer. In lung cancer, indirect cost accounted for the major portion of total 
estimated cost, e.g., for Germany 78% (Ruff 2000) to 89% (Weißﬂ og 2001). Indirect 
costs per case seem to increase with stage. In an Australian study, overall stage IV 
lung cancer patients had direct and indirect costs that were 19% higher than the 
average (Bishop 2009). The only indirect cost information on advanced NSCLC was 
reported by Romanus (2008) for the United States (mean wage loss per newly diag-
nosed end-stage IV NSCLC patient was $1697 [$126–$3371] in the ﬁ rst few months 
after diagnosis) and by Perrone (2004) for Italy (mean productivity loss per patient 
of c60,263). Employment rates of NSCLC patients were reported to be about 13% 
of NSCLC stage IIIb or IV, treated with 2nd line chemotherapy in Italy (Gridelli 2007). 
In the same population, the informal care given by the principal caregiver was the 
main assistance cost item with average 3-month cost of c2368 representing 74% of 
total assistance cost. CONCLUSIONS: The indirect cost burden of NSCLC has 
scarcely been assessed so far and needs further quantitative investigation, particularly 
in view of the use of new treatment options.
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OBJECTIVES: Bevacizumab-based therapy as ﬁ rst-line treatment of advanced or 
metastatic NSCLC is associated with longer progression-free survival (PFS) when 
compared with chemotherapy alone (Sandler et al. 2006; Reck et al. 2009). This study 
analyzes the implications of the clinical beneﬁ ts of bevacizumab-based treatment for 
the societal costs in Spain. METHODS: Clinical inputs (PFS) were obtained from two 
clinical trials (E4599 and AVAiL) comparing a bevacizumab regimen (combined with 
carboplatin/paclitaxel or cisplatin/gemcitabine) with chemotherapy alone. Percentage 
of patients returning to work was estimated as 20% of all progression-free patients 
with ECOG performance status 0–1 in the age of ≤55 years. PFS percentage was 
applied to the incidence estimation for nonsquamous metastatic NSCLC in Spain after 
applying speciﬁ c employment rate. Indirect costs were calculated using the human 
capital approach. Spanish labor costs available at EUROSTAT were applied after 
inﬂ ating to 2009 values. Employment patterns were suggested by the clinical experts 
(full time/part time), and were applied to the estimation of patients returning to work. 
Time frames for the calculations were 12 months and 18 months. RESULTS: Average 
cost saving per progression-free patient was c12,401 at 12 months and c22,322 at 18 
months. Sensitivity analysis on changes in employment patterns from 40% full 
time/60% part time to 60% full time/40% part time increased cost savings per patient 
to c14,173 and c25,511 at 12 and 18 months, respectively. CONCLUSIONS: Treat-
ment with bevacizumab-based therapy results in the reduction of productivity losses 
due to improved clinical beneﬁ ts and hereby leads to considerable societal cost savings.
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OBJECTIVES: The high societal cost of lung cancer derives mostly from productivity 
losses associated with premature retirement and premature mortality (Weißﬂ og et al. 
2001). Bevacizumab-based therapy is associated with signiﬁ cantly improved progres-
sion-free survival (PFS) over chemotherapy alone in patients with advanced or meta-
static NSCLC (Reck et al. 2009; Sandler et al. 2006), the most common form of lung 
cancer. The aim of this analysis was to assess the potential cost savings for Italy 
resulting from a higher number of progression-free metastatic NSCLC patients return-
ing to work while treated with bevacizumab-based therapy. METHODS: Productivity 
losses were calculated on the basis of number of days lost due to illness. Country labor 
costs and employment rates were taken from EUROSTAT. It was assumed, based on 
expert opinion, that 20% of progression-free patients with ECOG performance status 
0–1 and eligible to work would go back to their original employment status after the 
induction therapy. The percentage of PFS patients was calculated from two clinical 
